N/A N=100 Alternative Options to Minimize Niacin-Induced Flushing
Hypercholesterolemia · Flushing
Primary: Incidence of Flushing — 22; 18; 20; 23 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=373 Study of Indomethacin Capsules to Treat Pain Following Bunionectomy
Other Acute Postoperative Pain
Primary: The Time-Weighted Summed Pain Intensity Difference Measured Using the 100-mm Visual Analogue Scale From 0 to 48 Hours After Trial Entry (VASSPID-48) — 598.670; 623.162…
N/A N=1,209 An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease
Dry Eye Syndromes
Primary: Number of Participants Very Satisfied or Satisfied With OPTIVE PLUS® — 356; 746 Participants
Phase 4 N=20 Comparison of Pain of Conventional to Buffered Local Anesthesia During Injection in Pediatric Dental Patients
Pain
Primary: Participant Pain Experience After Administration of Local Anesthesia to Numb the Gums and Teeth During Dental Treatment — 43; 33.1; 7.3; 9.8 units on a scale — p=0.23
Phase 4 N=8,709 Randomized Study Comparing Endeavor With Cypher Stents (PROTECT)
Ischemic Heart Disease
Primary: To Compare Overall Definite or Probable Stent Thrombosis Rate of the Endeavor® Zotarolimus Eluting Coronary Stent System Versus the Cypher® Sirolimus-eluting Coronary…
N/A N=200 TAPP Inguinal Hernia Repair With Self-fixating Parietex™ ProGrip™ Mesh
Postoperative Complications
Primary: Proportion of Subjects Who Experience Hernia Recurrence (Defect Treated Initially With Parietex™ ProGrip™) Within 12 Months Post-surgery. — 3 participants
Phase 2 N=76 Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
Cervical Cancer
Primary: Tumor Response — 1; 7; 17; 34 participants
Phase 3 N=129 A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque-type Psoriasis
Psoriasis
Primary: Percentage of Participants Who Achieved a Greater Than Equal to 75 Percent Response in Psoriasis Area and Severity Index (PASI) — 81; 2.2 percentage of participants…
Phase 2 N=58 Dose-Intense Temozolomide in Recurrent Glioblastoma
Glioblastoma · Gliosarcoma
Primary: 6 Month Progression Free Survival — 11 percentage of evaluable participants
Phase 1 N=59 Cumulative Irritation Potential of 828 Ointment
Healthy Volunteers
Primary: Presence of Cumulative Irritation — 163.0; 109.0; 2073.0 units on a scale
Phase 3 N=130 Long-term Safety Study for GSK573719/GW642444 in Japanese
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) Throughout the Treatment Period — 113; 16 Participants
N/A N=90 A Dose Ranging Effect of Preoperative Diphenhydramine on Postoperative Quality of Recovery After Ambulatory Surgery
Surgery · Pain
Primary: Quality of Recovery 40 at 24 Hours — 164; 169; 172 units on scale 40 (low) - 200 (high)
Phase 4 N=36 Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients
Relapsing Remitting Multiple Sclerosis
Primary: Difference Serum Levels of High-sensitive C-reactive Protein (Hs-CRP), Before and After of Supplementation — 1.2; -0.6 mg/L — p=<0.01
Phase 2 N=23 Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
Primary: Maximum T Cell Response From Baseline — 10.5; 51.75; 270.625 spots per 10^4 CD8+ cells — p=0.028
N/A N=733 Radial Artery Versus Saphenous Vein Grafts in Coronary Artery Bypass Surgery
Cardiovascular Disease · Coronary Artery Disease
Primary: To Compare 1-year Angiographic Patency of Radial Artery Grafts Versus Saphenous Vein Grafts in Patients Undergoing Elective Coronary Artery Bypass Graft (CABG) Surgery…